NASDAQ:XENE Xenon Pharmaceuticals Q3 2026 Earnings Date & Estimates $37.62 +0.21 (+0.56%) Closing price 11/2/2026 04:00 PM EasternExtended Trading$37.08 -0.53 (-1.42%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xenon Pharmaceuticals is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Xenon Pharmaceuticals in Q3 2026Xenon Pharmaceuticals is expected to post earnings of -$1.13 per share on revenue of $1.33 million. In the same quarter a year earlier Xenon Pharmaceuticals reported -$1.15 per share. Xenon Pharmaceuticals last reported on August 6, 2026, posting -$1.11 per share and beating the -$1.16 consensus estimate. Xenon Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.13Expected Revenue$1.33 millionPrior-Year EPS-$1.15Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.11 (Beat by +$0.05)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Xenon Pharmaceuticals Q3 2026 Earnings FAQ When does Xenon Pharmaceuticals report Q3 2026 earnings? Xenon Pharmaceuticals (NASDAQ:XENE) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Xenon Pharmaceuticals' Q3 2026 earnings call? Xenon Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Xenon Pharmaceuticals? Analysts expect Xenon Pharmaceuticals to post earnings of -$1.13 per share for Q3 2026. How much revenue is Xenon Pharmaceuticals expected to report? The consensus revenue estimate for Xenon Pharmaceuticals is $1.33 million for Q3 2026. Xenon Pharmaceuticals Earnings HeadlinesXenon to Report Third-Quarter 2026 Results November 9November 2 at 8:53 PM | tipranks.comXenon to Report Q3 2026 Financial Results on November 9, 2026November 2 at 4:01 PM | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 3 at 1:00 AM | Behind the Markets (Ad)Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 30, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 30, 2026 | globenewswire.comXenon Reports Promising Pain Data, Targets Phase 2 Trials For Two Drug CandidatesOctober 29, 2026 | rttnews.comSee More Xenon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenon Pharmaceuticals and other key companies, straight to your email. Email Address About Xenon PharmaceuticalsXenon Pharmaceuticals (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for neurological and psychiatric disorders. The company uses expertise in human genetics and ion-channel biology to identify potential treatments for diseases with significant unmet medical needs, particularly epilepsy and other disorders of the nervous system. Xenon's lead investigational product is azetukalner, also known as XEN1101, a selective potassium-channel opener being evaluated for epilepsy and other potential neurological and psychiatric applications. The company also maintains a broader pipeline of programs targeting ion channels and neuronal signaling pathways, including candidates developed through internal research and strategic collaborations. Founded in 1996 and headquartered in Vancouver, British Columbia, Xenon conducts research and clinical development activities in North America and works with partners to advance selected programs. Ian Mortimer has served as the company's president and chief executive officer since 2016. Xenon Pharmaceuticals trades on the Nasdaq under the symbol XENE.View Xenon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
